(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42977 SC II Acquisition Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Exact name of registrant as specified in its charter) Cayman Islands 98-1876716 (State or other juris ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-39787 BIOATLA, INC. (Exact name of registrant as specified in its charter) Delaware 85-1922320 (State or other juris ...

Financial Overview - As of December 31, 2025, the Trust Account held $176,338,275, which is the amount available for the initial business combination [22]. - The Initial Public Offering generated gross proceeds of $172,500,000 from the sale of 17,250,000 units at $10.00 per unit [19]. - The Private Placement Units generated gross proceeds of $3,518,250 from the sale of 351,825 units at $10.00 per unit [20]. - The Company has borrowed $250,000 through a convertible unsecured promissory note to fund working capital needs [39]. - The Company has not commenced any operations and does not expect to generate operating revenues until after the initial business combination [16]. - The Company may need to obtain additional financing prior to closing the initial business combination to cover transaction costs [39]. Business Combination Details - The Company has a 24-month period from the closing of the Initial Public Offering to consummate an initial business combination, extendable up to 30 months under certain conditions [28]. - The Business Combination Agreement with Crypto.com aims to establish a digital asset treasury, making the Combined Company the largest publicly traded Cronos treasury company [23]. - The Business Combination is expected to create significant financial value, with the largest digital asset treasury company to market cap ratio in history [29]. - The Company will issue 100,000,000 shares of the Combined Company's Class B Common Stock in exchange for 10% of the Cronos Assets [43]. - The Business Combination Agreement includes provisions for the contribution of 6,313,000,212 Cronos tokens and necessary physical devices to establish a validator node [42]. - The Company will issue three Earnout Warrants to TMTG, each exercisable for 7% of the Company's outstanding capital stock at the time of Closing [53]. Regulatory Environment - The company is classified as an "emerging growth company" and is eligible for certain exemptions from reporting requirements, which may affect the attractiveness of its securities to investors [56]. - The SEC reopened the comment period for a proposal to amend the definition of "exchange" to include digital asset trading systems, which could significantly impact digital asset trading venues [144]. - The U.S. Congress passed the GENIUS Act, establishing a federal regulatory framework for payment stablecoins, which may introduce new compliance costs for the Combined Company [140]. - The SEC's "Project Crypto" aims to develop a flexible regulatory framework for cryptocurrencies, which may include clarity on asset classification and custody services [144]. - The SEC filed a complaint against Coinbase in June 2023 for operating as an unregistered securities exchange, highlighting ongoing regulatory scrutiny in the digital asset space [146]. - The risk of regulatory changes could significantly impact the market for CRO and the Combined Company's business operations [146]. Market and Competition - The combined company may face significant competition and regulatory uncertainties in the digital asset market, impacting its business strategy and financial condition [66]. - The combined company operates in a highly competitive environment, facing competition from both traditional financial firms and other digital asset-focused companies [95]. - The emergence of alternative digital assets could negatively impact the price of CRO and the Combined Company's financial condition [104]. - The market conditions and overall sentiment towards CRO have been affected by negative publicity and regulatory scrutiny, which could impact investor confidence [80]. Risks and Challenges - The combined company's operating results and revenues may significantly fluctuate due to the volatile nature of its CRO holdings, which could adversely affect the market price of its Class A Common Stock [66]. - The combined company's ability to raise additional capital may be limited, which could adversely affect its business and initial strategy [74]. - The potential for significant liquidations of CRO by large holders, including those associated with bankruptcy proceedings, poses a risk to the market [82]. - The combined company's CRO acquisition strategy exposes it to risks associated with the volatility of CRO and potential non-performance by counterparties [89]. - The lack of diversification in the Combined Company's CRO holdings enhances the risks associated with its acquisition strategy [88]. - The Combined Company may experience significant legal and regulatory scrutiny, which could lead to investigations, fines, and penalties [130]. Operational Considerations - The Combined Company plans to engage in CRO-related activities, including staking and operating a validator node, but may face operational challenges and regulatory hurdles [79]. - The Combined Company will rely on Crypto.com for administrative and operational services, which may not align with the interests of the Combined Company or its shareholders [107]. - The Combined Company's CRO holdings will be reported at a significant discount relative to the market value due to U.S. GAAP accounting standards, potentially affecting financial position and investor confidence [136]. - The Combined Company does not expect to maintain insurance coverage for its CRO holdings, exposing it to risks of loss without liability coverage [135]. Security and Cyber Risks - Security breaches and cyberattacks are significant concerns, as past incidents have resulted in substantial losses in the digital asset space, which could impact the Combined Company's CRO [127]. - The risk of cyberattacks on the Combined Company's systems and third-party service providers could materially and adversely affect its business operations [129]. - The potential loss of private keys or inadequate custodial controls could result in the inability to access CRO holdings, adversely affecting the value of the Combined Company's Class A Common Stock [133]. Future Outlook - The Combined Company anticipates that macroeconomic conditions, such as interest rates and inflation, will influence its business operations and financial performance [84]. - The growth of the digital assets industry and the acceptance of CRO are subject to high uncertainty, influenced by public familiarity and institutional demand [150]. - The regulatory environment for digital assets in the U.S. and globally remains highly uncertain, with increasing scrutiny from various governmental organizations on crypto operations, potentially affecting the Combined Company's business and financial condition [152].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-42720 YORKVILLE ACQUISITION CORP. (Exact name of registrant as specified in its charter) | Cayman Islands | 98-1850073 | | --- | --- | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 sep For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38052 FORTE BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter) Delaware 26-1243872 (State or other jurisdic ...

Exhibit 99.1 Co-Diagnostics Reports Full Year 2025 Financial Results Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening Technology Leadership with AI Integration and Expanding IP Portfolio Salt Lake City, UT – March 31, 2026 – Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the developmen ...

Financial Performance - Mawson Infrastructure Group Inc. reported significant growth in revenue, with a year-over-year increase of 45% to $50 million[10]. - The company achieved a gross profit margin of 30%, reflecting improved operational efficiency compared to the previous year[10]. - Mawson's operational costs decreased by 10% due to improved energy procurement strategies[10]. - The company reported a 5% increase in Bitcoin mining efficiency, contributing to higher profitability[10]. - The company expects to maintain a positive cash flow and aims for a 20% increase in overall revenue for the next fiscal year[10]. Infrastructure Expansion - Mawson's digital infrastructure capacity expanded by 25% in the last quarter, now totaling 200 MW[10]. - Mawson anticipates a 15% increase in customer demand for digital colocation services in the upcoming quarter[10]. Strategic Initiatives - The company plans to invest $20 million in new technology development for AI and HPC markets over the next fiscal year[10]. - The company is exploring strategic partnerships to enhance its market presence and expand into new regions, particularly in North America[10]. - Mawson is actively pursuing acquisitions to bolster its digital asset management capabilities, targeting a deal valued at approximately $30 million[10].

Financial Performance - For Q4 2025, Omeros reported a net income of $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, in Q4 2024[3]. - Non-GAAP adjusted net income for Q4 2025 was $222.5 million, or $3.14 per share, while for the full year, it was $133.4 million, or $2.10 per share[12]. - Total revenue for the twelve months ended December 31, 2025, was $86,451,000, compared to a net loss of $3,350,000 for the same period in 2024[27]. - Basic net income per share for the three months ended December 31, 2025, was $1.22, compared to a loss of $0.54 in the same period of 2024[27]. - Non-GAAP adjusted net income for the three months ended December 31, 2025, was $222,489,000, significantly higher than the adjusted net income of $133,367,000 for the same period in 2024[34]. Cash and Investments - As of December 31, 2025, Omeros had $171.8 million in cash and short-term investments and reduced its total debt by 46.7% to $87.9 million[10]. - Cash and cash equivalents increased to $9,660,000 as of December 31, 2025, from $3,400,000 in 2024, representing a growth of 184%[29]. - Total assets rose to $325,632,000 as of December 31, 2025, compared to $277,079,000 in 2024, indicating a 17.5% increase[29]. - Total liabilities decreased to $446,863,000 as of December 31, 2025, from $475,000,000 in 2024, reflecting a reduction of approximately 6%[29]. Research and Development - The company received a $6.24 million grant from NIDA to develop OMS527 for cocaine use disorder, with preclinical studies showing no safety issues[13]. - Research and development expenses for the three months ended December 31, 2025, were $19,446,000, a decrease of 16% from $23,320,000 in the previous year[27]. Product Development and Approvals - The FDA approved YARTEMLEA® for treating TA-TMA, marking it as the first approved therapy for this condition, with commercial distribution starting in January 2026[6][7]. - The company expects to commercialize YARTEMLEA in the U.S. and EU following EMA approval, with plans for marketing authorization applications in Europe[22]. Transactions and Milestones - The company recognized a net gain of $237.6 million from the zaltenibart transaction with Novo Nordisk, which included an upfront cash payment of $240.0 million[3][9]. - Omeros is eligible for up to $1.3 billion in milestone payments from Novo Nordisk based on sales and commercial milestones related to zaltenibart[4]. - The company reported a gain on the sale of zaltenibart amounting to $237,594,000 for the twelve months ended December 31, 2025[27]. Operating Expenses - Total operating expenses for 2025 were $122.8 million, down from $167.0 million in 2024, primarily due to reduced manufacturing costs[15]. - Interest expense decreased by $25.6 million in 2025, mainly due to changes in non-cash remeasurement costs related to the OMIDRIA royalty obligation[16]. Revenue from Royalties - Omeros earned $9.2 million in OMIDRIA royalties from U.S. net sales of $30.7 million in Q4 2025, compared to $10.1 million from $33.6 million in Q4 2024[14].

Financial Performance - Total revenue decreased 9.0% quarter-over-quarter to $49.7 million for Q4 2025, while full year revenue increased 2.0% to $212.5 million[5]. - Net loss before income taxes for the full year was $20.3 million, equating to ($0.59) per diluted share of Class A common stock[26]. - Loss from operations was $12.2 million for Q4 2025, or (24.5)% of total revenue, with restaurant-level adjusted EBITDA margin at 13.8% for the full year[5][21]. - Adjusted EBITDA was negative $2.7 million for Q4 2025, compared to a positive $2.0 million in the prior year[24]. - Net loss for Q4 2025 was $12,086,000, compared to a net loss of $1,397,000 in Q4 2024, reflecting a significant decline in profitability[39]. - Adjusted EBITDA for Q4 2025 was $(2,670,000), down from $2,056,000 in Q4 2024, indicating operational challenges[43]. - The company reported a net loss margin of 24.3% for Q4 2025, compared to 2.6% in Q4 2024[41]. - The net loss for the twelve months ended December 31, 2025, was $19,375,000, compared to a net income of $4,532,000 for the previous year[46]. - Adjusted Net Loss Income attributable to GEN Restaurant Group, Inc. for the three months ended December 31, 2025, was $(757,000), translating to an adjusted net loss per share of $(0.14)[46]. Revenue and Sales - Revenue for Q4 2025 was $49,746,000, a decrease of 9.8% compared to $54,654,000 in Q4 2024[39]. - Gift card sales to Costco totaled $29 million in 2025, a 150% increase from 2024[5][8]. - Comparable restaurant sales performance declined by 11.7% in Q4 2025, compared to a 4.8% decline in Q4 2024[41]. Operational Metrics - The company opened 15 new locations in 2025, exceeding its target of 12 to 13 new stores, bringing the total to 57 locations[5]. - The number of restaurants at the end of Q4 2025 was 57, an increase from 43 in Q4 2024[41]. - Total restaurant operating expenses for Q4 2025 were $49,673,000, slightly up from $49,581,000 in Q4 2024[39]. - For the three months ended December 31, 2025, the company reported a loss from operations of $12,197,000, resulting in an operating margin of -24.5%[44]. - The Restaurant-Level Adjusted EBITDA for the twelve months ended December 31, 2025, was $29,380,000, with a margin of 13.8%[44]. Expenses and Liabilities - General and administrative expenses increased to $25.9 million in 2025, up from $21.3 million in 2024, primarily due to increased marketing fees[25]. - Total assets increased to $259,856,000 as of December 31, 2025, up from $240,415,000 in 2024[41]. - Total liabilities rose to $231,850,000 as of December 31, 2025, compared to $194,798,000 in 2024[41]. - The company incurred impairment expenses of $5,527,000 during the twelve months ended December 31, 2025[44]. - Pre-opening costs for the twelve months ended December 31, 2025, amounted to $8,317,000, compared to $7,607,000 in the previous year[44]. - Stock-based compensation expenses for the twelve months ended December 31, 2025, totaled $2,936,000[46]. - The company recognized a non-cash lease expense of $474,000 for the twelve months ended December 31, 2025[44]. Strategic Initiatives - The Consumer-Packaged-Goods (CPG) division is projected to expand to 1,500 to 2,000 grocery locations by the end of 2026, and 7,000 to 8,000 locations by the end of 2027[5][16]. - The CPG business is expected to be a meaningful growth driver with strong margins, and the company plans to work with investment bankers to explore growth opportunities[18]. - The company is managing its restaurant portfolio and has entered into a joint venture with Chubby Cattle International for 5 non-performing restaurants[6]. - The company plans to continue expanding its restaurant locations and enhancing its product offerings in the future[36]. Legal and Settlement - The company recorded a legal settlement gain of $346,000 for the twelve months ended December 31, 2025[46].

IPO and Financial Proceeds - The company completed its IPO on March 3, 2025, raising gross proceeds of $230,000,000 from the sale of 23,000,000 Units at $10.00 per Unit, including 3,000,000 Units from the underwriters' over-allotment option [237]. - The company incurred total fees of $15,557,879 related to the IPO, which included a cash underwriting fee of $4,000,000 and a deferred underwriting fee of $10,950,000 [244]. - The company has engaged an advisor for capital markets services, agreeing to pay a non-refundable cash fee of 5.0% of the gross proceeds from financing transactions, with a minimum fee of $3,000,000 [259]. Financial Performance - For the year ended December 31, 2025, the company reported a net income of $4,130,222, primarily from interest income of $7,854,908 on marketable securities held in the Trust Account, offset by operating costs of $3,724,686 [243]. - As of December 31, 2025, the company had approximately $237,854,908 in marketable securities in the Trust Account, including interest income [247]. - The company has a working capital deficit of $2,410,655 as of December 31, 2025, with cash of $543,258 available for operations [249]. - The company has not generated any operating revenues to date and will not do so until after completing its initial business combination [242]. Business Combination and Future Plans - The company plans to use funds from the Trust Account primarily to complete its business combination and for working capital of the target business [247]. - The company may seek to extend the Combination Deadline, which requires approval from Public Shareholders, who will have the opportunity to redeem their shares [241]. - Management has raised substantial doubt about the company's ability to continue as a going concern if the initial business combination is not completed by the Combination Deadline [253]. Accounting and Reporting - The preparation of financial statements involves estimates and assumptions that can materially affect reported amounts of assets, liabilities, income, and expenses [261]. - Class A Ordinary Shares subject to possible redemption are classified as temporary equity and presented at redemption value outside of shareholders' equity [262]. - Net income (loss) per Ordinary Share is calculated using the two-class method, allocating net income (loss) pro rata to different classes of shares [263]. - No recently issued accounting standards are expected to have a material effect on the financial statements if adopted [264]. Board of Directors Changes - Gary Cookhorn resigned from the board of directors on March 17, 2026, without any disagreement with the company [265]. - Donald H. Putnam was appointed as a director on March 20, 2026, effective immediately [266]. Regulatory Classification - The company is classified as a smaller reporting company and is not required to provide additional market risk information [267].